HomeCompareHBLRX vs ABBV

HBLRX vs ABBV: Dividend Comparison 2026

HBLRX yields 7.42% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $64.1K in total portfolio value
10 years
HBLRX
HBLRX
● Live price
7.42%
Share price
$14.53
Annual div
$1.08
5Y div CAGR
5.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$38.2K
Annual income
$2,316.25
Full HBLRX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HBLRX vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHBLRXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HBLRX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HBLRX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBLRX
Annual income on $10K today (after 15% tax)
$631.05/yr
After 10yr DRIP, annual income (after tax)
$1,968.81/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $19,087.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBLRX + ABBV for your $10,000?

HBLRX: 50%ABBV: 50%
100% ABBV50/50100% HBLRX
Portfolio after 10yr
$70.3K
Annual income
$13,544.01/yr
Blended yield
19.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HBLRX
No analyst data
Altman Z
29495.5
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBLRX buys
0
ABBV buys
0
No recent congressional trades found for HBLRX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHBLRXABBV
Forward yield7.42%3.06%
Annual dividend / share$1.08$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR5.5%40.6%
Portfolio after 10y$38.2K$102.3K
Annual income after 10y$2,316.25$24,771.77
Total dividends collected$14.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HBLRX vs ABBV ($10,000, DRIP)

YearHBLRX PortfolioHBLRX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,483$783.24$11,550$430.00$67.00ABBV
2$13,174$886.81$13,472$627.96$298.00ABBV
3$15,099$1,003.11$15,906$926.08$807.00ABBV
4$17,290$1,133.59$19,071$1,382.55$1.8KABBV
5$19,780$1,279.84$23,302$2,095.81$3.5KABBV
6$22,608$1,443.65$29,150$3,237.93$6.5KABBV
7$25,818$1,626.94$37,536$5,121.41$11.7KABBV
8$29,457$1,831.85$50,079$8,338.38$20.6KABBV
9$33,579$2,060.76$69,753$14,065.80$36.2KABBV
10$38,246$2,316.25$102,337$24,771.77$64.1KABBV

HBLRX vs ABBV: Complete Analysis 2026

HBLRXStock

The investment seeks to provide current income with growth of capital as a secondary objective. The fund targets an allocation of approximately 45% equity securities and 55% fixed income investments, with the allocation generally varying by no more than +/-5%. The equity portion of the fund invests primarily in common stocks with a history of above-average dividends or expectations of increasing dividends. It may invest up to 20% of the fixed income portion of the portfolio in domestic non-investment grade debt.

Full HBLRX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HBLRX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBLRX vs SCHDHBLRX vs JEPIHBLRX vs OHBLRX vs KOHBLRX vs MAINHBLRX vs JNJHBLRX vs MRKHBLRX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.